Skip to content

Jio Platforms partners with Subex HyperSense AI to augment its 5G product line

By asianet

Subex, a provider of Telecom Analytics Solutions and AI-led Digital Trust products to communication service providers, and Jio Platforms Limited (JPL) a leading Indian Technology Company (subsidiary of RIL [NSE: RELIANCE]), today announced a partnership for its AI Orchestration Platform, HyperSense, which can enable telcos to deliver on the promise of AI across the data … Continued

Detect Technologies announces global agreement with Vedanta

By asianet

Detect Technologies [https://detecttechnologies.com/] announces a global agreement with Vedanta for deployment of T-Pulse [https://detecttechnologies.com/project-management/hsse/], their internationally deployed AI-based workplace safety software. Vedanta Resources Limited is a globally diversified natural resources company and is among the top producers of major commodities, including zinc-lead-silver, iron ore, steel, copper, aluminium, oil and gas. The group engages more than … Continued

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

By asianet

EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for … Continued

SK hynix Develops World’s Highest 238-Layer 4D NAND Flash

By asianet

-World’s first 238-layer 512Gb TLC 4D NAND developed in July; expected to begin mass production in the first half of 2023 -Providing highest, smallest NAND product while remarkably improving productivity, data transfer speed and power efficiency -“Will continue innovations to find breakthroughs in technological challenges” SK hynix Inc. (or “the company”, www.skhynix.com) announced today that … Continued

CELEBRATING CULTURAL REVIVAL AND THE TRADITION OF PASSING ON GENERATIONAL KNOWLEDGE THROUGH A NEW ROYAL CANADIAN MINT COIN HONOURING THE RED RIVER MÉTIS

By asianet

IN THE HEART OF THE NATIONAL HOMELAND OF THE RED RIVER MÉTIS — The Red River Métis tradition of sharing and preserving knowledge by passing it on from one generation to the next through art and storytelling is celebrated on a new fine silver coin showcasing the tradition of Red River Métis beadwork. This latest … Continued

CLA Nearly Triples Office Space with ESRT at One Grand Central Place

By asianet

Empire State Realty Trust, Inc. ( https://www.esrtreit.com/ ) (NYSE: ESRT) announced today that CLA (CliftonLarsonAllen LLP) ( https://www.claconnect.com/en ), the eighth largest accounting firm in the United States, expanded to lease the entire 51st floor of One Grand Central Place for a total of 12,422 square feet. CLA is tripling in size at the building … Continued

LOWER SOCIOECONOMIC STATUS IN CHILDHOOD, PERSISTENT LOW WAGES LINKED TO RISK FOR DEMENTIA AND FASTER MEMORY DECLINE

By asianet

Socioeconomic deprivation, including neighborhood disadvantages and persistent low wages, are associated with higher dementia risk, lower cognitive performance and faster memory decline, according to several studies reported today at the Alzheimer’s Association International Conference(R) (AAIC(R)) 2022 ( https://c212.net/c/link/?t=0&l=en&o=3608645-1&h=3881122162&u=https%3A%2F%2Fwww.alz.org%2Faaic&a=Alzheimer%27s+Association+International+Conference ) in San Diego and virtually. Socioeconomic status (SES) — reflecting both social and economic measures of … Continued

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

By asianet

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today … Continued